Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer-Associated Fibroblasts Promote Vasculogenic Mimicry of Colorectal Cancer by Epigenetic Silencing of Decorin [RNA-Seq]

ABSTRACT: Cancer-Associated Fibroblasts Promote Vasculogenic Mimicry of Colorectal Cancer by Epigenetic Silencing of Decorin [RNA-Seq]

PROVIDER: PRJNA1130974 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Investigating vasculogenic mimicry in breast cancer

Project description:Investigating vasculogenic mimicry in breast cancer

| PRJNA971220 | ENA

Gene expression of osteosarcama cell line with vasculogenic mimicry phenotype

Project description:Vasculogenic mimicry has been generally accepted as a new form of tumor vascularization and regarded as an unfavorable prognostic factor in multiple aggressive malignancies. We previously reported the presence of vasculogenic mimicry in osteosarcoma patients. The mechanistic basis for osteosarcoma VM remains unclear. We used microarrays to detail the global programme of gene expression between 143B cells and HOS cells exposed to Matrigel which showed greatly different vasculogenic mimicry formation potential and identified distinct classes of vasculogenic mimicry-realted genes during this process.

2018-09-15 | GSE119975 | GEO

Role of EGR1 in vasculogenic mimicry of MDA-MB-231 cells

Project description:Vasculogenic mimicry (VM) is an intriguing phenomenon observed in tumor masses, in which cancer cells organize themselves into capillary-like channels that closely resemble the structure and function of blood vessels. Although VM is believed to contribute to alternative tumor vascularization, the detailed regulatory mechanisms controlling these cellular processes remain poorly understood. Our study aimed to investigate the role of Early Growth Response 1 (EGR1) in regulating VM in aggressive cancer cells, specifically MDA-MB-231 triple-negative breast cancer cells.

2023-08-15 | GSE240489 | GEO

DDX5 super-enhancer promote vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription

Project description:Antiangiogenetic therapies (AATs) have limited effects owing to most patients with cancer inevitably developing resistance to them. In this study, data generated using a nasopharyngeal carcinoma orthotopic mouse model in combination with clinical data suggested compensatory vasculogenic mimicry (VM) formation during AATs and the association of VM with poor prognosis of nasopharyngeal carcinoma. Additionally, data-independent acquisition mass spectrometry-based proteomics demonstrated that ADAM10 upregulation contributes to VM. Mechanistically, epigenetic and high-resolution chromatin interaction landscape analyses revealed that while ADAM10 does not interact with either the proximal or distal enhancers, DDX5, a transcription factor of ADAM10, is regulated by long-range looping enhancer-promoter interactions. Further analysis identified transcription factors bound to critical constituents of the DDX5 super-enhancer. Ingenol Mebutate, which docked excellently with DDX5, reversed ADAM10-mediated changes in gene expression, thereby effectively suppressing compensatory VM formation and metastasis and improving prognosis. Collectively, these findings provide insights into the clinical application of AATs.

2025-04-02 | GSE263286 | GEO

DDX5 super-enhancer promote vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription

2025-04-02 | GSE263067 | GEO

Erianin abrogates vasculogenic mimicry through targeting m5C methylase NSUN2

Project description:Erianin abrogates vasculogenic mimicry through targeting m5C methylase NSUN2

| PRJNA1181520 | ENA

DDX5 super-enhancer promote vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription [Hi-C]

2025-04-27 | GSE283675 | GEO

Inhibitor of DNA binding-1, a master regulator of vasculogenic mimicry by cancer cells.

Project description:Inhibitor of DNA binding-1, a master regulator of vasculogenic mimicry by cancer cells.

| PRJNA1139094 | ENA

Erianin abrogates vasculogenic mimicry through targeting m5C methylase NSUN2

Project description:Purpose: The precise temporal and spatial regulation of N5-methylcytosine (m5C) RNA modification plays essential roles in RNA metabolism. Targeting m5C regulation in cancer cells may be a potential strategy for cancer therapy. Erianin is a natural product isolated from Dendrobium chrysotoxum Lindl. Howbeit, the in‐depth understanding of interaction between erianin and m5C modification remains indistinct. Methods: Natural product library screening was used to explore the effects of natural product monomers on uveal melanoma (UM) cells. Intraocular xenografts model was established to examine the effect of erianin. Immunoprecipitation mass spectrometry (IP-MS) and molecular docking analyses were performed to identify NSUN2 as the target of erianin. m5C-meRIP-seq and m5C-meRIP-qPCR analyses were performed to identify the functional target of NSUN2. Tube formation assay and CD31-PAS double staining were used to detect vasculogenic mimicry (VM) in UM. Results: Herein, we report the discovery of erianin as an effective inhibitor of uveal melanoma. Mechanistically, the targeted inhibition of NSUN2 function by erianin results in a decrease in the m5C modification and expression levels of CHAC1 in UM, thereby curtailing the formation of VM. Conclusions: Collectively, our data suggested that erianin significantly inhibited UM progression in vitro and in vivo. Our study unveils a novel therapeutic strategy for combating UM.

2024-12-10 | GSE280936 | GEO

Gene expression of osteosarcama cell line with vasculogenic mimicry phenotype

Project description:Gene expression of osteosarcama cell line with vasculogenic mimicry phenotype

| PRJNA490884 | ENA